Switch to
More onapp

IND Swift Laboratories Ltd

INDSWFTLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹383 cr, stock is ranked 1,455
Moderate RiskStock is 2.59x as volatile as Nifty
63.900.60 (-0.93%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹383 cr, stock is ranked 1,455
Moderate RiskStock is 2.59x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-178.54
PB RatioPB Ratio
0.64
Dividend YieldDiv. Yield
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ind-Swift Laboratories Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs). The Company operates through the bulk drugs and pharmaceuticals segment. The Company has a product portfolio of approximately 50 products across approximately 15 therapeutic segments. It manufactures Clarithromycin powder/granules, Atorvastatin Calcium Crystalline, Roxithromycin and Nitazoxanide. It also manufactures Nateglinide, Dutasteride, Moxifloxacin and Imatinib Mesylate. The Company offers products for various therapeutic categories, such as macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsyhotic, bone resorption inhibitor, hyperparathyrodism, antineoplastic, treatment of premature ejaculation and nootropic. Its research and development projects include Crams for API Development Medicinal Chemistry development for various discovery projects. The Company also operates a menthol and mint products manufacturing facility.

Financial TrendFinancial statements 

20192020202120220.880.810.911.080.03-0.02-0.00-0.00
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 21, 2022

Ind-Swift Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Ind-Swift Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Loss of share certificate 
Announced OnNov 10, 2022

Ind-Swift Laboratories Limited has informed the Exchange about Loss of share certificate | Download

Ind-Swift Laboratories Limited has informed the Exchange about Loss of share certificate | Download

Cash Dividend 
Ex. DateSep 20, 2011

Final • Div/Share: ₹ 1

See all events